Journal Logo



  • Free

In the article by Fourrier, published in the supplement to the November 2004 issue of Critical Care Medicine, page S539, right column, line 16, should read as follows.

An increase in adverse bleeding events is unlikely except in severe consumption coagulopathy (platelets <30,000/mm3; fibrinogen <1 g/L; prothrombin time <30%; grade E).

The author regrets the error.


1. Fourrier F: Recombinant human activated protein C in the treatment of severe sepsis: An evidence-based review. Crit Care Med 2004; 32[Suppl]:S534–S541
    © 2005 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins